AmpliPhi announces pre-clinical data

Efficacy of a bacteriophage cocktail is comparable to Vancomycin in S. aureus lung infection model

21-Sep-2015 - USA

AmpliPhi Biosciences Corporation announced experimental results highlighting that its prototype bacteriophage cocktail demonstrated comparable efficacy to vancomycin in reduction of Staphylococcus aureus (S. aureus) in a murine lung infection model.

“We are encouraged by these positive results, which demonstrate comparable efficacy between our investigational bacteriophage therapy and a standard of care therapy like vancomycin for S. aureus infections,” said M. Scott Salka, Chief Executive Officer of AmpliPhi. “These data provide valuable insight as we continue to evaluate and optimize an effective phage-based therapeutic cocktail for combating S. aureus, a potentially lethal bacteria that has demonstrated widespread resistance to traditional antibiotics.”

To assess the in vivo efficacy of bacteriophages to treat lung infections, neutropenic immunocompromised (ICR) mice were inoculated intranasally with S. aureus. At two hours post infection, scaled dosing of the bacteriophage cocktail was administered intranasally to three dosage groups (50 µl; n=5 for each group), with a second identical dose administered at six hours post infection. Vancomycin was administered subcutaneously at two and six hours post infection to a fourth, positive control group. Two control groups were infected, but untreated. The groups treated with the bacteriophage cocktail at the two highest doses (1 x 109 and 1 x 108 PFU per phage per dose) showed a 3-log reduction in bacterial cell counts relative to untreated controls at the same time point, which was comparable to the efficacy seen in the positive control group treated with vancomycin.

https://www.bionity.com/en/news/154654/ampliphi-announces-pre-clinical-data.html